Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome [PDF]
Anais Brasileiros de Dermatologia, 2017 Deferasirox is an iron chelator agent used in the treatment of diseases with iron overload, such as thalassemia and myelodysplastic syndrome. Although the majority of adverse reactions of deferasirox involve gastrointestinal symptoms and increase in ...
Asude Kara Polat +3 more
doaj +4 more sources
Cancer Medicine, 2019 Deferasirox is an oral iron‐chelating agent having possible antileukemia and immune modulatory effects. Few reports have evaluated deferasirox in the setting of allogeneic hematopoietic stem cell transplantation (allo‐HSCT). We investigated the impact of
Yoo-Jin Kim +2 more
exaly +2 more sources
Deferasirox improved iron homeostasis and hematopoiesis in ovariectomized rats with iron accumulation [PDF]
Scientific ReportsMenopause is a natural biological aging process characterized by the loss of ovarian follicular function and decrease estrogen levels. These hormonal fluctuations are associated with increased iron levels, which ultimately lead to iron accumulation. This
Niloofar Honari +4 more
doaj +2 more sources
The Possible Protective Role of Vitamin E Against Deferasirox-Induced Injury of Renal Cortical Tubules in Adult Male Albino Rat: A Histological and Immunohistochemical Study [PDF]
The Egyptian Journal of Histology, 2023 Introduction: Deferasirox, as an oral iron chelator, is presently the first-choice medication for iron overload caused by repeated blood transfusions due to its ease of use, efficacy, and high bioavailability, yet deferasirox has been also reported with ...
Shimaa Badr +2 more
doaj +1 more source
Molecules, 2021 Deferasirox is an orally active, lipophilic iron chelating drug used on thousands of patients worldwide for the treatment of transfusional iron overload. The essential transition metals iron and copper are the primary catalysts of reactive oxygen species
Viktor A. Timoshnikov +4 more
doaj +1 more source
Development and Validation of a Method for Determining Deferasirox in Human Blood Plasma by HPLC-UV
Разработка и регистрация лекарственных средств, 2022 Introduction. Deferasirox is one of the most well-known complexing drugs chelators and is successfully used in chelating therapy for the treatment of excess iron in the human body. Deferasirox is also included in the list of vital and essential medicines,
P. A. Karpova +7 more
doaj +1 more source
Efficacy and Side Effects of Deferasirox and Deferiprone for Thalasemia Major in Children [PDF]
Pharmacology and Clinical Pharmacy Research, 2016 Thalassemia major (TM) is an inherited disease caused by defective or absent of hemoglobin chain synthesis. Regular chelation therapy is necessary to reduce excess iron in several organs of TM patients.
Asti Y. Rindarwati +2 more
doaj +1 more source
Evaluation of Hepatic Enzymes in major β-thalassemic Patients using Deferasirox
Iraqi Journal of Pharmaceutical Sciences, 2022 β-thalassemia major is a genetic disease that causes sever defect in normal hemoglobin synthesis. The patients with β-thalassemia major need periodic blood transfusions that can result in accumulation of body iron, so treatment with iron chelating agent ...
Ahmed Yahya Dallal Bashi +1 more
doaj +1 more source
Complex interaction of deferasirox and Pythium insidiosum: iron-dependent attenuation of growth in vitro and immunotherapy-like enhancement of immune responses in vivo. [PDF]
PLoS ONE, 2015 Pythium insidiosum iron acquisition mechanisms are unknown. We previously showed that the iron chelator deferasirox had weak activity in vitro and in rabbits with experimental pythiosis. Here we show that deferasirox causes damage to P. insidiosum hyphae
Régis A Zanette +10 more
doaj +1 more source
Haematologica, 2023 CALYPSO (clinicaltrials gov. Identifier: NCT02435212), a randomized, open-label, multicenter, phase II study evaluated the compliance, clinical benefits, and safety of deferasirox granules and dispersible tablets (DT) in pediatric patients with iron ...
Ali T. Taher +8 more
doaj +1 more source